(NASDAQ: NAGE) Niagen Bioscience's forecast annual revenue growth rate of 6.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 42.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.56%.
Niagen Bioscience's revenue in 2026 is $122,290,000.On average, 8 Wall Street analysts forecast NAGE's revenue for 2026 to be $9,565,401,944, with the lowest NAGE revenue forecast at $9,150,410,173, and the highest NAGE revenue forecast at $9,881,397,587. On average, 7 Wall Street analysts forecast NAGE's revenue for 2027 to be $11,021,041,021, with the lowest NAGE revenue forecast at $9,864,766,238, and the highest NAGE revenue forecast at $11,754,404,343.
In 2028, NAGE is forecast to generate $12,672,296,449 in revenue, with the lowest revenue forecast at $10,804,041,507 and the highest revenue forecast at $14,314,048,248.